Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Eur Urol. 2015 May 16;70(1):45–53. doi: 10.1016/j.eururo.2015.04.039

Fig. 1.

Fig. 1

Flow diagram of specimens in the training and validation cohort. Specimen cohorts for all urine samples assessed for TMPRSS2:ERG (T2:ERG) and PCA3 are shown. Samples excluded from various analyses (indicated by legend and described in the text) are indicated in red. Samples assessed using version 2 or version 3 (final assay) T2:ERG transcription-mediated amplification assays are indicated.

AS= active surveillance; EDRN = Early Detection Research Network; PCPTrc = Prostate Cancer Prevention Trial risk calculator; PCPThg = PCPT high grade cancer risk calculator; PSA = prostate-specific antigen; ROC = receiver operating characteristic; T2:ERG = TMPRSS2:ERG;UMHS = University of Michigan Health System; v3 = version 3.